D3.1 Molecular Tumour Board Portal Interoperability

This report details the advancements made in Task 3.1, specifically within the Deliverable D3.1, focusing on the
enhancement of interoperability between clinical trial databases and Clinical Decision Support Systems (CDSS)
for oncology. The Molecular tumour Board Portal (MTBP) and TrialMatchAI are central to our efforts,
automating the integration and interpretation of diverse molecular and clinical data to support precision cancer medicine across European cancer centers. MTBP, developed at Karolinska Institutet, streamlines the capture and analysis of next-generation sequencing data, linking functional genomic alterations with clinical outcomes and trial opportunities. Complementarily, TrialMatchAI leverages state-of-the-art artificial intelligence, particularly large language models, to automate the matching of patient profiles with clinical trials, focusing on genomic biomarkers and other relevant patient data to generate tailored clinical trial recommendations. This system not only increases the efficiency of patient-trial matching but also enhances the precision of treatment decisions. APIs ensure seamless data flow and integration with CDSS, aiming to significantly impact the landscape of cancer treatment and research by providing a robust framework for data-driven orientation of patients to clinical trials.